DermTech, Inc. (NASDAQ:DMTK) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC grew its holdings in DermTech, Inc. (NASDAQ:DMTK – Get Rating) by 158.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 227,871 shares of the company’s stock after purchasing an additional 139,677 shares during the period. Rafferty Asset Management LLC’s holdings in DermTech were worth $3,600,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. Advisor Group Holdings Inc. lifted its holdings in shares of DermTech by 14.7% in the 3rd quarter. Advisor Group Holdings Inc. now owns 4,719 shares of the company’s stock worth $152,000 after acquiring an additional 606 shares during the last quarter. US Bancorp DE boosted its position in shares of DermTech by 160.1% during the third quarter. US Bancorp DE now owns 1,009 shares of the company’s stock worth $32,000 after buying an additional 621 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of DermTech by 73.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,950 shares of the company’s stock valued at $63,000 after buying an additional 826 shares during the period. Royal Bank of Canada grew its position in DermTech by 13.1% in the 3rd quarter. Royal Bank of Canada now owns 8,803 shares of the company’s stock valued at $282,000 after acquiring an additional 1,018 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of DermTech by 13.5% in the third quarter. Commonwealth Equity Services LLC now owns 9,037 shares of the company’s stock valued at $290,000 after purchasing an additional 1,075 shares during the period. 75.12% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $38.00 price objective (down from $48.00) on shares of DermTech in a research note on Thursday, April 14th. Zacks Investment Research cut DermTech from a “hold” rating to a “sell” rating in a research note on Thursday, April 21st. Craig Hallum cut their target price on shares of DermTech from $50.00 to $37.00 in a research note on Wednesday, March 2nd. Lake Street Capital reduced their target price on shares of DermTech from $79.00 to $34.00 in a report on Wednesday, March 2nd. Finally, Cowen lowered their price target on shares of DermTech from $33.00 to $20.00 in a report on Wednesday, May 4th.

In related news, CEO John Dobak sold 2,561 shares of DermTech stock in a transaction on Monday, March 7th. The shares were sold at an average price of $13.03, for a total value of $33,369.83. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Herm Rosenman purchased 20,000 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were purchased at an average price of $6.86 per share, for a total transaction of $137,200.00. Following the completion of the purchase, the director now owns 72,832 shares of the company’s stock, valued at $499,627.52. The disclosure for this purchase can be found here. Insiders have sold a total of 7,037 shares of company stock worth $95,384 in the last 90 days. 3.60% of the stock is currently owned by company insiders.

DMTK stock opened at $7.37 on Tuesday. DermTech, Inc. has a twelve month low of $6.39 and a twelve month high of $48.32. The company’s 50 day moving average is $11.60 and its two-hundred day moving average is $15.04.

DermTech (NASDAQ:DMTK – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.12). DermTech had a negative net margin of 716.51% and a negative return on equity of 37.83%. During the same quarter in the previous year, the firm earned ($0.49) earnings per share. As a group, analysts predict that DermTech, Inc. will post -3.9 earnings per share for the current year.

DermTech Company Profile (Get Rating)

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

Featured Stories